UBS Group set a $20.00 price target on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report released on Monday, December 18th, thefly.com reports. The brokerage currently has a hold rating on the stock.
A number of other research firms have also recently issued reports on TEVA. BidaskClub upgraded shares of Teva Pharmaceutical Industries from a strong sell rating to a sell rating in a research note on Wednesday, September 13th. Gabelli reiterated a buy rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. Maxim Group reiterated a hold rating and issued a $15.50 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. BTIG Research reiterated a buy rating and issued a $24.00 target price on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 4th. Finally, Barclays set a $21.00 target price on shares of Teva Pharmaceutical Industries and gave the company an equal weight rating in a research note on Wednesday, October 4th. Seven analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $21.61.
Teva Pharmaceutical Industries (NYSE TEVA) traded up $1.70 during midday trading on Monday, reaching $21.74. The company’s stock had a trading volume of 35,268,433 shares, compared to its average volume of 25,430,000. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $37.94. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $21,500.00, a P/E ratio of -3.70, a price-to-earnings-growth ratio of 1.36 and a beta of 0.54.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.27%.
Hedge funds have recently made changes to their positions in the company. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $106,000. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the period. Penserra Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $129,000. Shelter Mutual Insurance Co acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at $133,000. Finally, Fieldpoint Private Securities LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $171,000. 51.98% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/11/teva-pharmaceutical-industries-teva-pt-set-at-20-00-by-ubs.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.